Summit Therapeutics Inc. (SMMT)
| Market Cap | 98.12M |
| Revenue (ttm) | 1.87M |
| Net Income (ttm) | -92.51M |
| Shares Out | 98.12M |
| EPS (ttm) | -0.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80,338 |
| Open | 0.96 |
| Previous Close | 0.89 |
| Day's Range | 0.95 - 1.01 |
| 52-Week Range | 0.88 - 8.39 |
| Beta | 1.04 |
| Analysts | Sell |
| Price Target | 4.08 (+308.0%) |
| Earnings Date | Aug 9, 2022 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infecti... [Read more...]
Financial Performance
In 2021, SMMT's revenue was 1.81 million, an increase of 110.35% compared to the previous year's 860,000. Losses were -88.60 million, 68.1% more than in 2020.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for SMMT stock is "Sell." The 12-month stock price forecast is 4.08, which is an increase of 308.00% from the latest price.
News
Summit Therapeutics' Rights Offering Nearing Expiration Date
Summit Provides Preliminary Update on Financial Position Summit Provides Preliminary Update on Financial Position
Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President
Bob Duggan Remains Chairman of the Board of Directors and CEO Bob Duggan Remains Chairman of the Board of Directors and CEO
Summit Therapeutics Announces Commencement of $100 Million Rights Offering
Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the Com...
Summit Therapeutics Provides Update on Ridinilazole
Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of ridinila...
Summit Therapeutics Announces $100 Million Rights Offering
Menlo Park, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company's Board of Directors has approved a rights offering...
Summit Therapeutics' Upcoming Annual Shareholders' Meeting
Rescheduled to June 16, 2022, at 1:00pm Eastern Time Rescheduled to June 16, 2022, at 1:00pm Eastern Time
Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer
Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately.
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progr...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended Dece...
Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics field Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics ...
Summit Therapeutics Announces Rights Offering
Cambridge, Massachusetts, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company's Board of Directors has approved a right...
Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company's v...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc. - SMMT
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to ...
Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company's vision and its intended...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100...
LOS ANGELES, Dec. 31, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Summit Therapeutics Inc...
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to ...
LOS ANGELES--(BUSINESS WIRE)---- $SMMT #SMMT--INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm
Summit Therapeutics' Infection Candidate Flunks In Head-To-Head Trial
Summit Therapeutics Inc (NASDAQ: SMMT) shares are trading lower after disappointing results from the Phase 3 Ri-CoDIFy study of ridinilazole for C. difficile infection (CDI).
Why Summit Therapeutics Stock Is Tumbling Today
The company just revealed disappointing phase 3 trial results for its only clinical-stage drug candidate.
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluating its inve...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ende...
Cambridge, Massachusetts, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its o...
Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte G...
Cambridge, Massachusetts, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte Gayko, PhD, has been appointed to our Board of Directors, effective imme...
Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors
Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately. M...
(SMMT) Alert: Did You Lose Money on Your Summit Therapeutics Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO, Oct. 2, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Summit Therapeutics Inc. ("Summit" or the ...
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investig...
Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek is the jo...
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...
FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection Trials
Summit Therapeutics Inc (NASDAQ: SMMT) announced that the FDA disagrees with its proposed change to the primary endpoint in Phase 3 Ri-CoDIFy studies. In a regulatory filing, the Company said that the f...